Commercial Credit Report for Biolingus Cayman Ltd

CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals. Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue. We also offer solutions that can help ease private company financial risk assessment. Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively.

A partial report preview for Biolingus Cayman Ltd is shown below. Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database. To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

	Biolingus Cayman Ltd
Grossmatt 6
	HERGISWIL, 6052 Switzerland

Business Summary

Biolingus Cayman Ltd is a Switzerland based holding Company, that operates in the biotechnology industry. The main and only segment that is undertaken by the Company is the development of oral, sublingual, delivery systems, in the more common sense, these are casings for various drugs that are to be taken orally. These systems, that are developed by the Company, are able to deliver peptides, and various proteins for chronic diseases, such as diabetes, obesity, and inflammatory diseases. The business operations are conducted through the Companies subsidiaries. The locations of the subsidiaries that the business operates through are in Switzerland, Hong Kong, the People’s Republic of China, and Australia.

Scores and Ratings

FRISK^® Score	Z'' Score	PAYCE^® Score	DBT Index	Moody's Rating	Fitch Rating	DBRS Rating
-	Yes	-	-	-	-	-

Financials, News and Filings

Latest Statement	Last Audit	News	SEC Filings	Bankruptcy Filings	Suit & Judgment Filings	Tax Lien Filings
4/30/2023	4/30/2023	-	Yes	-	-	-

Industries

SIC Code	Description
2834	Pharmaceutical preparations
3841	Surgical and medical instruments and apparatus
6719	Offices of holding companies, not elsewhere classified

Officers and Directors

Title	Name	Age	Title Date	Start Date
Chairman of the Board, Chief Executive Officer	YvesDecadt	56
Chief Financial Officer	Chun PongHui	38	1/1/2023	1/1/2023
Director	Sai YingKo	77
3 additional Officers and Directors records available in full report.

General Information

Outstanding Shares:

11,112,582

(As of 12/19/2023)

SITE MAP | ABOUT US | DIRECTORY | STOCK QUOTE: CRMZ | SIGN IN